Literature DB >> 19583488

Cases of borderline in vitro constitutive thyrotropin receptor activity: how to decide whether a thyrotropin receptor mutation is constitutively active or not?

Sandra Mueller1, Hulya Iliksu Gozu, Rifat Bircan, Holger Jaeschke, Markus Eszlinger, Julia Lueblinghoff, Knut Krohn, Ralf Paschke.   

Abstract

BACKGROUND: Previous in vitro data for several constitutively activating thyrotropin receptor (TSHR) mutations reported divergent results for the constitutive activity of the same mutations. Moreover, several case reports have highlighted the difficulties in determining whether a TSHR mutation is constitutively active or not. Retrospectively, this has repeatedly been the case for mutants with only a slight increase of basal cAMP activity. We re-examined 10 previously described TSHR germline mutations with minor increases of basal cAMP activity and analyzed the influences of the cell line and vector system on the basal receptor activity.
METHODS: TSHR mutations were characterized by determination of cell surface expression, cAMP accumulation, and linear regression analysis of constitutive activity.
RESULTS: Re-examination of the previously described constitutively active TSHR germline mutations did not show constitutive activity for R310C and N670S as tested in COS-7 cells and confirmed constitutive activity for the other eight mutations. However, mutant N670S showed a slight but significant increase of basal activity measured by linear regression analysis when analyzed in HEK(GT) cells transiently transfected with pcDNA but not with the pSVL vector. This was not the case for R310C.
CONCLUSIONS: Our findings indicate that current methods to precisely classify mutants with only a slight increase of the basal activity as constitutively active are limited. The results concerning the level of the basal activity can be influenced by the vector and/or the cell system. A comprehensive clinical characterization of the respective patients appears as a necessary and promising adjunct for the activity classification of these borderline mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19583488     DOI: 10.1089/thy.2009.0006

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  6 in total

1.  TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia.

Authors:  Kathrin Müller; Dagmar Führer; Jens Mittag; Nora Klöting; Matthias Blüher; Roy E Weiss; Marie-Christine Many; Kurt Werner Schmid; Knut Krohn
Journal:  Mol Endocrinol       Date:  2011-10-06

2.  Database(d) Guidelines: A Small World.

Authors:  Patrice Rodien
Journal:  Eur Thyroid J       Date:  2012-10

3.  2012 European thyroid association guidelines for the management of familial and persistent sporadic non-autoimmune hyperthyroidism caused by thyroid-stimulating hormone receptor germline mutations.

Authors:  R Paschke; M Niedziela; B Vaidya; L Persani; B Rapoport; J Leclere
Journal:  Eur Thyroid J       Date:  2012-10-04

4.  Principles and determinants of G-protein coupling by the rhodopsin-like thyrotropin receptor.

Authors:  Gunnar Kleinau; Holger Jaeschke; Catherine L Worth; Sandra Mueller; Jorge Gonzalez; Ralf Paschke; Gerd Krause
Journal:  PLoS One       Date:  2010-03-18       Impact factor: 3.240

5.  Lack of consistent association of thyrotropin receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism.

Authors:  J Lueblinghoff; S Mueller; J Sontheimer; R Paschke
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

6.  The W520X mutation in the TSHR gene brings on subclinical hypothyroidism through an haploinsufficiency mechanism.

Authors:  S Moia; M Godi; G E Walker; M Roccio; P Agretti; M Tonacchera; R Berardi; S Bellone; F Prodam; M Giordano; G Bona
Journal:  J Endocrinol Invest       Date:  2013-04-08       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.